Search

everythinglearnresearchcommunity

for

Search:↓

The CDC reports 23 measles cases in unvaccinated US kids, new treatments for eosinophilic esophagitis and osteopenia are approved, poor sleep may cause migraines, atopic dermatitis could lead to asthma, migraines might increase Crohn's disease risk, cancer may raise heart disease risk, gout is linked to prostate issues, Cabo Verde is malaria-free, social factors and vitamin D affect dementia risk, smoking increases hair loss risk, certain drugs might lower thyroid disease risk in arthritis, noma is a neglected disease, and meal timing could impact heart health.

Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.

Fat tissue's stromal-vascular fraction has stem cells that could be used for regenerative medicine, but official treatment protocols are not yet approved.

Female pattern hair loss is common and should be treated early to prevent worsening, with Minoxidil being the main approved treatment.

Exosomes, tiny cell-released particles, may help hair growth, but their exact role is unclear, they're not FDA-approved, and their unregulated use can cause side effects.

Lurasidone is effective for bipolar depression and schizophrenia, but more safety data is needed.

Docetaxel slightly extends prostate cancer survival but has significant side effects and high cost.

Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.

Teriflunomide effectively reduces relapse rates and disease progression in multiple sclerosis but is not safe for use during pregnancy.

Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.

Minoxidil can slow hair loss and promote regrowth but won't fully restore hair.

Lasers and light treatments are now the most common ways to remove hair.

Divalproex sodium can unexpectedly cause agitation and hyperactivity in some patients.

Certain compounds can boost hair and nail growth.

Flutamide helps with prostate cancer and some skin conditions but can harm the liver.

Aminoacridine and Minoxidil together show promise for better hair and nail growth.

Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.

Afatinib, neratinib, and zanubrutinib could be effective against KRASG12C-mutant tumors.

Minoxidil solution and foam both increase hair growth, but the solution works better than the foam.

Dupilumab for eczema may cause hair loss.

Deoxycholic acid is effective for reducing chin fat but can cause side effects and serious complications, so careful patient evaluation is needed.

Abrocitinib shows promise for treating various skin conditions beyond atopic dermatitis.

Trodelvy™ helped some patients with advanced breast cancer, but had side effects.

Old psychiatric drugs are increasingly being used for new purposes, and technologies like SmartCube® help create new drugs.

The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.

The Journal of Cutaneous and Aesthetic Surgery is now included in PubMed.

Baricitinib effectively regrows hair in severe alopecia areata cases.

The document concludes that current hair loss treatments have limitations and suggests researching new treatments targeting different factors of hair loss.

Provenge extends prostate cancer survival by about 4 months.

Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.